Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EIGR NASDAQ:LJPC NASDAQ:NVAX NASDAQ:STRO NASDAQ:TARA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEIGREiger BioPharmaceuticals$4.35$1.10▼$43.35$2.55M1.83103,866 shs137,800 shsLJPCLa Jolla Pharmaceutical$5.73$3.07▼$6.24$155.11M2.39158,476 shs66,708 shsNVAXNovavax$7.13+1.2%$6.77$5.01▼$17.81$1.15B2.696.28 million shs1.11 million shsSTROSutro Biopharma$0.80+2.4%$0.86$0.52▼$5.17$67.82M1.641.13 million shs36,841 shsTARAProtara Therapeutics$3.05+0.5%$3.16$1.60▼$10.48$117.67M1.35795,914 shs42,675 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEIGREiger BioPharmaceuticals0.00%0.00%0.00%0.00%0.00%LJPCLa Jolla Pharmaceutical0.00%0.00%0.00%0.00%0.00%NVAXNovavax+6.51%+6.51%-5.50%+4.30%-41.63%STROSutro Biopharma+5.90%+15.37%-7.49%+24.94%-74.19%TARAProtara Therapeutics+8.21%+8.21%-9.28%-24.25%+44.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEIGREiger BioPharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ALJPCLa Jolla PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/ANVAXNovavax4.4917 of 5 stars3.12.00.04.71.30.83.1STROSutro Biopharma3.2006 of 5 stars3.11.00.04.70.61.70.0TARAProtara Therapeutics1.6741 of 5 stars3.61.00.00.01.20.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEIGREiger BioPharmaceuticals 0.00N/AN/AN/ALJPCLa Jolla Pharmaceutical 0.00N/AN/AN/ANVAXNovavax 2.29Hold$17.00138.60% UpsideSTROSutro Biopharma 2.25Hold$6.11661.43% UpsideTARAProtara Therapeutics 3.14Buy$20.50573.23% UpsideCurrent Analyst Ratings BreakdownLatest NVAX, STRO, EIGR, LJPC, and TARA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025NVAXNovavaxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSell$6.006/16/2025STROSutro BiopharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$2.005/22/2025TARAProtara TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$21.005/19/2025NVAXNovavaxB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/19/2025STROSutro BiopharmaBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderperform ➝ Underperform$1.00 ➝ $0.805/9/2025NVAXNovavaxJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$9.00 ➝ $7.004/29/2025STROSutro BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.004/28/2025TARAProtara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.004/16/2025TARAProtara TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$12.00(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEIGREiger BioPharmaceuticals$15.77M0.00N/AN/A$37.68 per share0.00LJPCLa Jolla Pharmaceutical$75.72M0.00N/A7.95($2.94) per share0.00NVAXNovavax$682.16M1.69N/AN/A($3.89) per share-1.83STROSutro Biopharma$62.04M1.09N/AN/A$0.54 per share1.49TARAProtara TherapeuticsN/AN/AN/AN/A$4.77 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEIGREiger BioPharmaceuticals-$96.78M-$59.16N/AN/AN/A-590.80%-332.49%-99.77%N/ALJPCLa Jolla Pharmaceutical$19.66M$0.1251.840.00N/A8.54%-5.46%4.00%N/ANVAXNovavax-$187.50M$2.652.6989.060.0638.14%-115.51%29.99%8/14/2025 (Estimated)STROSutro Biopharma-$227.46M-$2.98N/AN/AN/A-373.66%-347.60%-59.46%8/12/2025 (Estimated)TARAProtara Therapeutics-$44.60M-$1.72N/AN/AN/AN/A-36.37%-33.29%8/5/2025 (Estimated)Latest NVAX, STRO, EIGR, LJPC, and TARA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025TARAProtara Therapeutics-$0.43N/AN/AN/AN/AN/A5/8/2025Q1 2025NVAXNovavax$0.71$2.93+$2.22$2.93$204.08 million$666.66 million5/8/2025Q1 2025STROSutro Biopharma-$0.63-$0.91-$0.28-$0.91$11.61 million$17.40 million5/8/2025Q1 2025TARAProtara Therapeutics-$0.47-$0.29+$0.18-$0.29N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEIGREiger BioPharmaceuticalsN/AN/AN/AN/AN/ALJPCLa Jolla PharmaceuticalN/AN/AN/AN/AN/ANVAXNovavaxN/AN/AN/AN/AN/ASTROSutro BiopharmaN/AN/AN/AN/AN/ATARAProtara TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEIGREiger BioPharmaceuticalsN/A3.313.24LJPCLa Jolla PharmaceuticalN/A4.023.52NVAXNovavaxN/A2.062.03STROSutro BiopharmaN/A2.162.16TARAProtara TherapeuticsN/A18.0318.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEIGREiger BioPharmaceuticals62.46%LJPCLa Jolla Pharmaceutical97.06%NVAXNovavax53.04%STROSutro Biopharma96.99%TARAProtara Therapeutics38.13%Insider OwnershipCompanyInsider OwnershipEIGREiger BioPharmaceuticals4.22%LJPCLa Jolla Pharmaceutical36.30%NVAXNovavax1.00%STROSutro Biopharma5.90%TARAProtara Therapeutics12.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEIGREiger BioPharmaceuticals561.48 million1.42 millionOptionableLJPCLa Jolla Pharmaceutical6124.94 million15.89 millionOptionableNVAXNovavax1,990161.97 million160.35 millionOptionableSTROSutro Biopharma24084.46 million79.48 millionOptionableTARAProtara Therapeutics3038.58 million33.76 millionOptionableNVAX, STRO, EIGR, LJPC, and TARA HeadlinesRecent News About These CompaniesProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - The Manila TimesJuly 2, 2025 | manilatimes.netMProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - MorningstarJuly 2, 2025 | morningstar.comMProtara Therapeutics, Inc. Added to Russell 3000® Index, Enhancing Visibility in Financial Community - NasdaqJuly 2, 2025 | nasdaq.comProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 1, 2025 | globenewswire.comProtara Therapeutics, Inc. Added to Russell 3000® Index, Enhancing Visibility in Financial CommunityJune 30, 2025 | quiverquant.comQProtara Therapeutics Announces Addition to the Russell 3000® IndexJune 30, 2025 | globenewswire.comProtara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Recommendation of "Buy" from AnalystsJune 30, 2025 | americanbankingnews.comProtara Therapeutics, Inc. (NASDAQ:TARA) Given Average Rating of "Buy" by BrokeragesJune 30, 2025 | marketbeat.comProtara Therapeutics, Inc. (TARA) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comRAPT Therapeutics Appoints Scott Braunstein, M.D. and Ashley Dombkowski, Ph.D. to Board of DirectorsJune 23, 2025 | quiverquant.comQProtara Therapeutics: Marching On To A Hopefully Eventful Back Half Of 2025June 14, 2025 | seekingalpha.comTwo Sigma Investments LP Cuts Stock Holdings in Protara Therapeutics, Inc. (NASDAQ:TARA)June 14, 2025 | marketbeat.comAnalysts Set Expectations for TARA FY2026 EarningsJune 10, 2025 | marketbeat.comChutes & Ladders—Protara gears up for next steps with commercial proJune 7, 2025 | fiercebiotech.comFThe Escalator: Digitas Health, Bristol Myers Squibb, Inizio Evoke and moreJune 4, 2025 | mmm-online.comMProtara Therapeutics names new Chief Commercial OfficerJune 4, 2025 | investing.comProtara Therapeutics Announces Appointment of William Conkling as Chief Commercial OfficerJune 2, 2025 | globenewswire.comJones Trading Initiates Coverage of Protara Therapeutics (TARA) with Buy RecommendationMay 23, 2025 | msn.comRichard Levy Spends US$64k On Protara Therapeutics StockMay 22, 2025 | finance.yahoo.comWith 73% ownership, Protara Therapeutics, Inc. (NASDAQ:TARA) boasts of strong institutional backingMay 16, 2025 | finance.yahoo.comProtara Therapeutics to Participate in Upcoming Investor ConferencesMay 13, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend3 AI Infrastructure Stocks With Strong Growth, Not HypeBy Chris Markoch | June 26, 2025View 3 AI Infrastructure Stocks With Strong Growth, Not HypeThese 3 Dividend Stocks Combine Strong Yields With UpsideBy Chris Markoch | June 20, 2025View These 3 Dividend Stocks Combine Strong Yields With UpsideChime’s Smart IPO: Half the Valuation, Double the StrengthBy Jeffrey Neal Johnson | June 18, 2025View Chime’s Smart IPO: Half the Valuation, Double the StrengthSuper Micro Computer Stock's Rally Backed by Strong FinancialsBy Gabriel Osorio-Mazilli | June 19, 2025View Super Micro Computer Stock's Rally Backed by Strong FinancialsNVAX, STRO, EIGR, LJPC, and TARA Company DescriptionsEiger BioPharmaceuticals NASDAQ:EIGREiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.La Jolla Pharmaceutical NASDAQ:LJPCLa Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts.Novavax NASDAQ:NVAX$7.12 +0.09 (+1.21%) As of 10:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.Sutro Biopharma NASDAQ:STRO$0.80 +0.02 (+2.36%) As of 10:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.Protara Therapeutics NASDAQ:TARA$3.04 +0.02 (+0.50%) As of 10:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.